 The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.Negative clinical readouts led to some strong selling in stocks such as Iterum Therapeutics PLC NASDAQ: ITRM and Novus Therapeutics Inc NASDAQ: NVUS. On a positive note, Merck Co., Inc. NYSE: MRK snagged another approval for its triple combo antibiotic.Here are are the key catalysts for the unfolding week.Conferences Bio Digital: June 8-12 41st Annual Goldman Sachs Global Healthcare Conference, held as a virtual event: June 9-11 The Endocrine Societys ENDO Online 2020: June 8-22 25th Edition of the European Hematology Association, or EHA, Annual Congress held in virtual format: June 11-21 American Academy of Dermatology, or AAD, Virtual Meeting Experience: June 12-14 The American Diabetes Association, or ADA, 80th Scientific Sessions - Virtual: June 12-16Related Link: Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In ClinicsPDUFA Dates The FDA is set to rule on Viela Bio Incs NASDAQ: VIE BLA for inebilizumab in treating neuromyelitis optica spectrum disorder, a rare autoimmune disorder. ThursdayClinical Readouts ENDO Online Presentations Opko Health Inc. NASDAQ: OPK: results from the global Phase 3 pediatric trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency MondayNeurocrine Biosciences, Inc. NASDAQ: NBIX: Results of the Phase 2 proof-of-concept study of crinecerfont in adult patients with congenital adrenal hyperplasia MondayEHA Presentations bluebird bio Inc NASDAQ: BLUE: data from its gene therapy programs for sickle cell disease, transfusion-dependent β-thalassemia and its cell therapy program for relapsed and refractory multiple myelomaMerus NV NASDAQ: MRUS: interim data from the Phase 1 MCLA-117 acute myeloid leukemia trial and an analysis of an extensive, proprietary panel of CD3 bispecific antibodiesBlueprint Medicines Corp NASDAQ: BPMC: results from Phase 2 PIONEER study of avapritinib in patients with indolent systemic mastocytosis and updated Phase 1 data for avapritinib in patients with advanced systemic mastocytosis, regardless of prior midostaurin therapyAutolus Therapeutics Ltd - ADR NASDAQ: AUTL: updated data using AUTO1 in relapsedrefractory B-Acute lymphoblastic leukemia, and Phase 1 data for AUTO3 with Mercks Keytruda in patients with relapsedrefractory diffuse large B cell lymphomaVertex Pharmaceuticals Incorporated NASDAQ: VRTX and Crispr Therapeutics AG NASDAQ: CRSP: 12 months of follow-up data for the first patient treated in the ongoing Phase 12 CLIMB-111 trial in transfusion-dependent beta thalassemia and six months of follow-up data for the first patient treated in the ongoing Phase 12 CLIMB-121 trial in severe sickle cell diseaseView more earnings on IBBTakeda Pharmaceutical Co Ltd NYSE: TAK: interim analysis from the Phase 2 OPTIC study of ponatinib in chronic-phase chronic myeloid leukemia patients who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.Imara Inc NASDAQ: IMRA: interim data from the ongoing Phase 2a study of IMR-687 in patients with sickle cell diseasePrincipia Biopharma Inc NASDAQ: PRNB: updates on efficacy and safety, including durability of effect, from the ongoing open-label Phase 12 clinical trial in patients with immune thrombocytopeniaConstellation Pharmaceuticals Inc NASDAQ: CNST: updated preliminary data from the MANIFEST clinical trial of CPI-0610 in myelofibrosisProtagonist Therapeutics Inc NASDAQ: PTGX: data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemiaAgios Pharmaceuticals Inc NASDAQ: AGIO: updated clinical proof-of-concept data from the Phase 2 study of mitapivat in in adults with non-transfusion-dependent thalassemiaAAD Presentations Principia Biopharma: full data set presentation from the Phase 2 Part B pemphigus trial with its investigational drug rilzabrutinib FridayADA Presentations Oramed Pharmaceuticals, Inc. NASDAQ: ORMP: poster presentations of oral insulin ORMD-0801s effects on glucose parameters in uncontrolled Type 2 diabetes, oral insulin-induced reduction in liver fat content in Type 2 diabetic patients with non-alcoholic steatohepatitis and evening oral insulin glycemic effects in uncontrolled Type 2 diabetes patients FridayvTv Therapeutics Inc. NASDAQ: VTVT: full clinical study results from the positive Phase 2 Simplici-T1 Study of TTP399 as an oral adjunctive therapy in type 1 diabetes SaturdayEarnings Enzo Biochem, Inc. NYSE: ENZ Monday, after the closeAdvaxis, Inc. NASDAQ: ADXS Thursday, before the market opensIPO Dallas, Texas-based clinical-stage biotech Lantern Pharma, which uses AI, machine language and genomic data to develop drugs and identify patients who can benefit from targeted oncology therapies, has filed to offer 1.563 million shares of its common stock at an estimated price range of 15-17. The shares of the company have been approved for listing on the Nasdaq under the ticker symbol LTRN.IPO Quiet Period Expiry ADC Therapeutics SA NYSE: ADCTSee more from Benzinga The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets 0M Bid The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Mercks Triple Combo Antibiotic The Daily Biotech Pulse: Regulatory Delay For Novartis Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 StudyC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 